KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of GoodwillCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Dividends Paid - CommonFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cvs Health (CVS) Capital Expenditures (2016 - 2025)

Historic Capital Expenditures for Cvs Health (CVS) over the last 17 years, with Q4 2025 value amounting to $784.0 million.

  • Cvs Health's Capital Expenditures rose 208.33% to $784.0 million in Q4 2025 from the same period last year, while for Dec 2025 it was $2.8 billion, marking a year-over-year increase of 183.39%. This contributed to the annual value of $2.8 billion for FY2025, which is 183.39% up from last year.
  • Per Cvs Health's latest filing, its Capital Expenditures stood at $784.0 million for Q4 2025, which was up 208.33% from $698.0 million recorded in Q3 2025.
  • In the past 5 years, Cvs Health's Capital Expenditures registered a high of $1.1 billion during Q1 2022, and its lowest value of $408.0 million during Q2 2022.
  • For the 5-year period, Cvs Health's Capital Expenditures averaged around $694.6 million, with its median value being $679.0 million (2022).
  • In the last 5 years, Cvs Health's Capital Expenditures soared by 4485.29% in 2023 and then crashed by 2835.37% in 2024.
  • Over the past 5 years, Cvs Health's Capital Expenditures (Quarter) stood at $597.0 million in 2021, then grew by 15.24% to $688.0 million in 2022, then soared by 32.41% to $911.0 million in 2023, then decreased by 15.7% to $768.0 million in 2024, then increased by 2.08% to $784.0 million in 2025.
  • Its Capital Expenditures stands at $784.0 million for Q4 2025, versus $698.0 million for Q3 2025 and $607.0 million for Q2 2025.